Clinical trial
A Randomized, Open-Label, Multicenter Phase II Clinical Study of Different Doses of Trastuzumab Rezetecan for Injection or Trastuzumab Deruxtecan for Injection in the Treatment of Unresectable Locally Recurrent/Metastatic Breast Cancer With HR-Positive and HER2-Low Expression
NCT07497386 is registered in ClinicalTrials.gov with Jiangsu HengRui Medicine Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Open-Label, Multicenter Phase II Clinical Study of Different Doses of Trastuzumab Rezetecan for Injection or Trastuzumab Deruxtecan for Injection in the Treatment of Unresectable Locally Recurrent/Metastatic Breast Cancer With HR-Positive and HER2-Low Expression
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- April 28, 2026
- Completion date
- December 31, 2028
- Enrollment
- 150 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
unresectable locally metastatic breast cancer, unresectable locally recurrent breast cancer